The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Purpose
To validate the association between body composition and mortality in men treated with radiation for localized prostate cancer (PCa). Secondarily, to integrate body composition as a factor to classify patients by risk of all‐cause mortality.
Materials and Methods
Participants of NRG/Radiation Therapy Oncology Group (RTOG) 9406 and NRG/RTOG 0126 with archived computed tomography were included...
BACKGROUND
DNA damage repair mutations (DDRm) are common in patients with metastatic castration‐resistant prostate cancer (mCRPC). The optimal standard therapy for this population is not well described.
METHODS
A multi‐institutional, retrospective study of patients with mCRPC and DDRm was conducted. Patient data, including systemic therapies and responses, were collected. The decline in prostate‐specific...
Background
The progression of prostate cancer is a complex, multistep process that involves molecular alterations in cells of the tumor and the microenvironment, with associated interactions between the stroma and epithelium. Genomic expression analyses of stromal infiltration markers were performed to determine the significance thereof in prostate cancer.
Methods
Genome‐wide expression profiles...
Background
We sought to determine the extent to which US Preventive Services Task Force (USPSTF) 2012 Grade D recommendations against prostate‐specific antigen screening may have impacted recent prostate cancer disease incidence patterns in the United States across stage, National Comprehensive Cancer Network (NCCN) risk groups, and age groups.
Methods
SEER*Stat version 8.3.4 was used to calculate...
Background
Management for men aged ≤55 years with low‐risk prostate cancer (LRPC) is debated given quality‐of‐life implications with definitive treatment versus the potential missed opportunity for cure with conservative management. The objective of this study was to define rates of conservative management for LRPC and associated short‐term outcomes in young versus older men in the United States...
BACKGROUND
Definitive stereotactic body radiotherapy (SBRT) represents an emerging and debated treatment option for patients with prostate cancer, with potential economic savings and reports of short‐term efficacy since 2006. The current study sought to define national trends in definitive prostate SBRT use and determine whether patterns vary by travel distance for treatment.
METHODS
The National...
BACKGROUND
Stereotactic body radiation therapy (SBRT) for localized prostate cancer involves high‐dose‐per‐fraction radiation treatments. Its use is increasing, but concerns remain about treatment‐related toxicity. The authors assessed the incidence and predictors of a global decline in health‐related quality of life (HRQOL) after prostate SBRT.
METHODS
From 2008 to 2014, 713 consecutive men with...
BACKGROUND
Most major cancer organizations seek to reduce sociodemographic disparities in high‐risk cancers partly by increasing access to theoretically high‐quality, academic‐oriented cancer care. The objective of this study was to determine whether academic centers have less sociodemographic treatment disparities than community centers using high‐risk prostate cancer as a test case.
METHODS
The...
BACKGROUNDIn the current study, the authors sought to both characterize the national trends in proton therapy use for prostate cancer and determine the factors associated with receipt of this limited resource, using what to the best of their knowledge is the largest nationwide cancer registry.
METHODSThe National Cancer Data Base was used to identify 187,730 patients diagnosed with nonmetastatic...
BACKGROUNDThe presence of Gleason pattern 5 (GP5) at radical prostatectomy (RP) has been associated with worse clinical outcome; however, this pathologic variable has not been assessed in patients receiving salvage radiation therapy (SRT) after a rising prostate‐specific antigen level.
METHODSA total of 575 patients who underwent primary RP for localized prostate cancer and subsequently received...
BACKGROUND:The objective of this study was to determine whether the addition of low‐dose‐rate brachytherapy or androgen‐deprivation therapy (ADT) improves clinical outcome in patients with high‐risk prostate cancer (HiRPCa) who received dose‐escalated radiotherapy (RT).
METHODS:Between 1995 and 2010, 958 patients with HiRPCa were treated at Schiffler Cancer Center (n = 484) or at the University of...
BACKGROUND:After external beam radiation therapy (EBRT) for prostate cancer, a short interval to biochemical failure of <18 months has been proposed as a surrogate for cause‐specific survival. Because EBRT dose influences biochemical failure, the authors investigated the interval to biochemical failure in a cohort of patients treated with dose‐escalated EBRT.
METHODS:From 1998 to 2008, 710 patients...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.